{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:58Z","timestamp":1793963098424,"version":"4.8.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe the effects of daratumumab-based therapy in 20 patients admitted with a new diagnosis of MM and AKI with a median creatinine of 6.5 mg\/dL. All patients (100%) achieved serum free light chain (sFLC) reduction \u226550% within the first cycle, with a median time to sFLC reduction \u226550% of 3 days (95% confidence interval [CI], 3-7). Of 17 patients, 15 (88%) achieved sFLC reduction \u2264500 mg\/L after 1 cycle of treatment. The median time to sFLC reduction \u2264500 mg\/L was 14.5 days (95% CI, 9-49). The overall renal response at 3 months was 85% (n = 17), with complete, partial, and minor responses in 50% (n = 10), 10% (n = 2), and 25% (n = 5), respectively. Of the 9 patients who required dialysis at presentation, 4 of 7 (57.1%) and 6 of 7 (85.7%) were dialysis independent at 3 and 12 months, respectively. Hematologic overall response rate was 100%, with very good partial response (VGPR) in 90%. With a median follow-up of 25 months, progression-free survival was 46.5 months (95% CI, 11.9 to not reached), and the 2-year overall survival was 83.7% (95% CI, 68.4-100). These findings highlight the importance of early initiation of daratumumab-based treatment in patients with MM and AKI to induce rapid and significant reductions in sFLCs, improve renal outcomes, and provide an approach without plasmapheresis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015901","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T22:31:46Z","timestamp":1741991506000},"page":"3129-3135","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury"],"prefix":"10.1182","volume":"9","author":[{"given":"E. Bridget","family":"Kim","sequence":"first","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Malespini","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-6065","authenticated-orcid":false,"given":"Matthew","family":"Lei","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Han","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole W.","family":"Minsky","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-581X","authenticated-orcid":false,"given":"Diana","family":"Cirstea","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025062511215383800_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"2025062511215383800_bib2","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025062511215383800_bib3","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025062511215383800_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025062511215383800_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis (Basel)"},{"issue":"6","key":"2025062511215383800_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"2025062511215383800_bib7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2025062511215383800_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"33","key":"2025062511215383800_bib9","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025062511215383800_bib10","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025062511215383800_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"13","key":"2025062511215383800_bib12","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025062511215383800_bib13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2215\/CJN.01640216","article-title":"Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy","volume":"11","author":"Finkel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"2025062511215383800_bib14","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.2019003807","article-title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","volume":"135","author":"Royal","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025062511215383800_bib15","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","article-title":"Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma","volume":"103","author":"Rocchi","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2025062511215383800_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-023-00806-w","article-title":"Multiple myeloma with acute light chain cast nephropathy","volume":"13","author":"Leung","year":"2023","journal-title":"Blood Cancer J"},{"issue":"21","key":"2025062511215383800_bib17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"2025062511215383800_bib18","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025062511215383800_bib19","doi-asserted-by":"crossref","first-page":"e3293","DOI":"10.1002\/hon.3293","article-title":"Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy","volume":"42","author":"Dima","year":"2024","journal-title":"Hematol Oncol"},{"issue":"4","key":"2025062511215383800_bib20","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 16","key":"2025062511215383800_bib21","article-title":"A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency [abstract]","volume":"41","author":"Harvey","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025062511215383800_bib22","article-title":"Effect of daratumumab on renal outcome in newly diagnosed multiple myeloma with light chain cast nephropathy","volume":"144","author":"Yabi","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3129\/2381597\/blooda_adv-2025-015901-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3129\/2381597\/blooda_adv-2025-015901-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:21:59Z","timestamp":1750864919000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3129\/536049\/Early-daratumumab-therapy-improves-renal-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015901","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,7,8]]}}}